Research summaries

Plain-English summaries of pre-clinical and translational research on healing peptides, written for the laboratory researcher and informed reader.

• 2026-02-11

  BPC-157 in tendon healing — what the 2024 evidence base shows

  BPC-157 has the largest and most consistently positive pre-clinical tendon-healing dataset of any research peptide. Across more than two dozen independent rodent studies of Achilles transection, supraspinatus tear, medial collateral ligament injury, and Achilles tendinopathy, treated tendons have shown faster recovery of biomechanical strength, improved collagen fibril alignment, accelerated tenocyte repopulation, and enhanced peritendinous angiogenesis compared with saline controls. The mechanistic story — growth-hormone-receptor upregulation in tenocytes, VEGFR2-driven angiogenesis, and NO-system protection of the peritendinous vasculature — is coherent and reproducible across laboratories. The translation to human tendon care, however, remains entirely unproven: no controlled human trial of BPC-157 for any tendon indication has been published in an indexed journal as of 2024.

• 2026-03-02

  GHK-Cu and skin regeneration — what the dermal evidence shows

  GHK-Cu (glycyl-L-histidyl-L-lysine:copper(II)) has the strongest dermal regenerative evidence base of any non-prescription peptide ingredient. Five decades of laboratory characterisation, beginning with Pickart's 1973 discovery, have produced a coherent and reproducible picture: copper delivery to cuproenzymes (notably lysyl oxidase), broad transcriptional modulation in human fibroblasts, accelerated wound closure in animal models, and an extensive cosmetic-use safety record. The clinical translation, however, is uneven. Cosmetic-dermatology evidence is substantial; controlled trials in therapeutic wound-care indications are sparse and methodologically heterogeneous. This reference synthesises what the dermal evidence currently supports, what it does not, and where the most useful future research lies.

• 2026-04-10

  Best healing peptides for research in 2026

  This is a 2026 reference list of the most actively studied research peptides for tissue healing, repair, and regeneration. It is organised by evidence-base depth — not by commercial popularity, supplier prominence, or social-media visibility — and applies to laboratory research selection. BPC-157 remains the most-studied research peptide for soft-tissue repair; GHK-Cu leads dermal regeneration; KPV and larazotide dominate gut-barrier research; LL-37 sits at the antimicrobial-host-defence intersection. The peptides included on this list all have indexed peer-reviewed publications, plausible mechanism of action, and at least some independent replication outside the discovering laboratory. Compounds whose evidence is confined to a single laboratory or supplier marketing material are not included.

• 2026-05-17

  UK research peptide regulation in 2026 — a reference guide

  The UK regulatory position on research peptides sits across four distinct frameworks — MHRA medicines licensing, WADA anti-doping classifications, the Misuse of Drugs Act, and the Human Medicines Regulations 2012. This reference explains how each applies, and what the research-versus-supply distinction means in practice.